French nuclear meds specialist AAA agrees to $3.9 billion acquisition

30 October 2017
mergers-acquisitions-big

Shares of France-based Advanced Accelerator Applications (AAA; Nasdaq: AAAP) moved up 5.68% and a further 2.88% to $75.1012 in after-hours trading on Friday, ahead of the confirmation that is has received a takeover approach, which its board of directors had agreed to.

Swiss pharma giant Novartis (NOVN: VX) is proposing to commence a tender offer for 100% of the share capital of AAA subject to certain conditions, at a price of $41 per ordinary share of AAA and $82 per American Depositary Share (each representing 2 ordinary shares of AAA) subject to certain conditions. This offer values AAA's equity at $3.9 billion.

AAA is a radiopharmaceutical company that develops, produces and commercializes molecular nuclear medicines including Lutathera (Lutetium Lu 177 dotatate), a first-in-class RLT product for neuroendocrine tumors (NETs). Radiopharmaceuticals, such as Lutathera, are unique medicinal formulations containing radioisotopes which are used clinically for both diagnosis and therapy. The transaction would strengthen Novartis' oncology presence with both near-term product launches as well as a new technology platform with potential applications across a number of oncology early development programs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology